Antiviral therapy is more effective in patients in the early stages of cirrhosis and less effective in patients with cirrhosis in the decompensated stage. If nucleoside antiviral drugs are used for treatment, the consent of the patient must be obtained and the treatment should be carried out under the close supervision of specialized doctors. Patients should not use the drugs without authorization because serious consequences may occur in case of viral mutation or random stopping of the drugs. When patients with cirrhosis undergo antiviral treatment, other comprehensive therapies used originally should not be neglected, especially for patients with decompensated cirrhosis, the treatment measures such as plasma and albumin supplementation often taken should not be ignored; patients with cirrhosis who have signs of infection should be given additional antibiotics to minimize the impact of endotoxemia on the liver. Hepatitis B cirrhosis patients must adhere to the antiviral treatment to the end, do not easily stop the drug, and, at least every 3 months of treatment should be tested, especially the serious condition of patients prone to kidney damage should be strengthened to monitor the treatment, only in this way, it is possible to get the ideal therapeutic effect. A large number of clinical studies have confirmed that even low-dose interferon can lead to a series of adverse reactions such as hepatitis attack or serious bacterial infections in some patients. For the sake of selecting the safety of the treatment, interferon is absolutely prohibited in patients with cirrhosis of hepatitis B in the decompensated stage, and at this time, the nucleoside analogs are the first-line antiviral drugs for this type of patients. According to the Asia-Pacific Association for the Study of Liver Diseases (APASL) Guidelines for the Management of Chronic Hepatitis B and the U.S. Guidelines for the Treatment of Hepatitis B: For patients with decompensated liver function or those who are about to undergo decompensation, telbivudine, entecavir, and adefovir can be used for initial treatment. As these patients require long-term antiviral therapy, indicators related to drug resistance should be closely monitored, and timely measures should be taken in case of drug resistance mutation.